• Markets
    • icon
  • Companies
ANR · ASX

Anatara Lifesciences Ltd (ASX:ANR)

AU$0.046

 -0.002 (-4.167%)
ASX:Live
19/09/2024 12:00:00 AM
HALO Ords GROWTH AUS All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

ANR Overview

ANR Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Strong

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About ANR

Website

N/A

Telephone

N/A

Address

Description

Anatara Lifesciences Ltd. engages in the development of non-antibiotic oral solutions for gastrointestinal diseases in animals and humans. It also develops and commercializes Detach, a non-antibiotic therapy that prevents and treats diarrhea in piglets. The company was founded by Tracey Mynott on July 15, 2010 and is headquartered in Adelaide, Australia.

ANR Price Chart

Key Stats

Market Cap

AU$9.26M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.02 - 0.05

Trade Value (12mth)

AU$1,818.00

1 week

-6.12%

1 month

-2.13%

YTD

109.09%

1 year

44.12%

All time high

1.66

Key Fundamentals

EPS 3 yr Growth

-66.60%

EBITDA Margin

N/A

Operating Cashflow

-$1m

Free Cash Flow Return

-109.00%

ROIC

-126.80%

Interest Coverage

N/A

Quick Ratio

5.50

Other Data

Shares on Issue (Fully Dilluted)

181m

HALO Sector

Healthcare

Next Company Report Date

02-Sep-25

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

ANR Announcements

Latest Announcements

Date Announcements

10 September 24

Anatara Annual General Meeting & Director Nominations

×

Anatara Annual General Meeting & Director Nominations

30 August 24

GaRP Irritable Bowel Syndrome Clinical Trial Update

×

GaRP Irritable Bowel Syndrome Clinical Trial Update

29 August 24

$626,000 received in R&D Tax Incentive for FY24

×

$626,000 received in R&D Tax Incentive for FY24

22 August 24

Appendix 4E & Financial Report 30 June 2024

×

Appendix 4E & Financial Report 30 June 2024

09 August 24

Notification regarding unquoted securities - ANR

×

Notification regarding unquoted securities - ANR

30 July 24

Appendix 4C & Q4 FY24 Activities Report

×

Appendix 4C & Q4 FY24 Activities Report

12 July 24

Change of Director's Interest Notice

×

Change of Director's Interest Notice

11 July 24

Notification regarding unquoted securities - ANR

×

Notification regarding unquoted securities - ANR

09 July 24

Application for quotation of securities - ANR

×

Application for quotation of securities - ANR

05 July 24

Results of Meeting

×

Results of Meeting

13 June 24

IBS Clinical Trial Stage 2 recruitment is proceeding well

×

IBS Clinical Trial Stage 2 recruitment is proceeding well

03 June 24

Notice of General Meeting/Proxy Form

×

Notice of General Meeting/Proxy Form

14 May 24

ANR- Cleansing Notice

×

ANR- Cleansing Notice

07 May 24

Application for quotation of securities - ANR

×

Application for quotation of securities - ANR

07 May 24

Notification regarding unquoted securities - ANR

×

Notification regarding unquoted securities - ANR

01 May 24

Anatara successful placement for $1.0M

×

Anatara successful placement for $1.0M

01 May 24

Proposed issue of securities - ANR

×

Proposed issue of securities - ANR

30 April 24

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

29 April 24

Trading Halt

×

Trading Halt

22 April 24

Change in substantial holding

×

Change in substantial holding

09 April 24

Recruitment 5 sites for Pivotal IBS Clinical Trial Stage 2

×

Recruitment 5 sites for Pivotal IBS Clinical Trial Stage 2

29 February 24

Recruitment for Pivotal Phase II IBS Clinical Trial Stage 2

×

Recruitment for Pivotal Phase II IBS Clinical Trial Stage 2

28 February 24

Appendix 4D & Half Year Report 31 December 2023

×

Appendix 4D & Half Year Report 31 December 2023

24 January 24

Appendix 4C & Q2 FY24 Activities Report

×

Appendix 4C & Q2 FY24 Activities Report

18 December 23

Anatara finalises Entitlement Issue

×

Anatara finalises Entitlement Issue

ANR Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.03 -0.02 -0.01 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.03 -0.02 -0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock -11.7 40.1 50.0 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.03 -0.02 -0.01 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.03 -0.02 -0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock -27.9 51.3 52.7 Lock Lock Lock
     Yield % Lock Lock Lock Lock -57.2 -82.4 -19.8 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.02 0.01 0.01 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.02 0.01 0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock -64.9 -58.4 -1.4 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 78 104 150 Lock Lock Lock
Basic m Lock Lock Lock Lock 78 104 150 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 3 3 2 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock -293.9 -0.3 90.1 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -3 -3 -2 Lock Lock Lock
     Growth % Lock Lock Lock Lock 3.5 -8.8 35.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -3 -3 -2 Lock Lock Lock
     Growth % Lock Lock Lock Lock 2.9 -8.7 36.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -3 -3 -2 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock 0 -1 -1 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -3 -2 -1 Lock Lock Lock
     Growth % Lock Lock Lock Lock -26.9 20.1 28.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -2 -2 -1 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 0 1 2 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -2 -2 -1 Lock Lock Lock
     Growth % Lock Lock Lock Lock -6.6 -0.9 44.8 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 1 0 1 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 2 1 2 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -1 0 -1 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Equity $m Lock Lock Lock Lock 1 1 1 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 1 1 1 Lock Lock Lock
     Growth % Lock Lock Lock Lock -63.8 -34.4 47.6 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -143.3 -142.5 -86.8 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -185.6 -218.8 -106.4 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -113.2 -279.0 -183.8 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -95.5 -173.4 -126.8 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -84.2 -193.5 -109.0 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Leverage
Interest Cover X Lock Lock Lock Lock -902.9 -1,375.6 N/A Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 0.4 0.1 0.5 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -80.9 -43.4 -72.0 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 4.7 2.9 5.5 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 4.7 2.9 5.5 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 68.8 28.3 58.8 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -623.5 -456.9 -410.1 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -143.3 -142.5 -86.8 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.3 1.5 1.2 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -185.6 -218.8 -106.4 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -185.6 -218.8 -106.4 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 2,575.9 1,705.6 24,172.2 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -2,575.9 -1,705.6 -24,172.2 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

ANR Shortsell

Frequently Asked Questions

The current share price of Anatara Lifesciences Ltd (ANR:ASX) is AU$0.046.
The 52-week high share price for Anatara Lifesciences Ltd (ANR:ASX) is AU$0.05.
The 52-week low share price for Anatara Lifesciences Ltd (ANR:ASX)? is AU$0.02.
Anatara Lifesciences Ltd (ANR:ASX) does not pay a dividend.
Anatara Lifesciences Ltd (ANR:ASX) does not pay a dividend.
Anatara Lifesciences Ltd (ANR:ASX) has a franking level of 0.0%.
Anatara Lifesciences Ltd (ANR:ASX) is classified in the Healthcare.
The current P/E ratio for Anatara Lifesciences Ltd (ANR:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.